Drug resistance is a common concern for the development of novel antiviral, antimicrobial and anticancer therapies. To overcome
this problem, several strategies have been developed, many of which involving the theme of this review, the use of structure-based
drug design (SBDD) approaches. These include the successful design of new compounds that target resistant mutant proteins, as well as
the development of drugs that target multiple proteins involved in specific biochemical pathways. Finally, drug resistance can also be
considered in the early stages of drug discovery, through the use of strategies to delay the development of resistance. The purpose of this
brief review is to underline the usefulness of SBDD approaches based on case studies, highlighting present challenges and opportunities
in drug design.